NYC-Based Cannabis Brand Silly Nice Beats Chinese Tariffs with American-Made Packaging
Silly Nice partners with Sana Packaging to cut international costs and champion sustainability.
Title: The Full Silly Nice Lineup – Premium Weed with Eco-Friendly Packaging
Sustainably Sealed – Recycled Glass Jars with Ocean-Bound Plastic Lids
New York, NY, April 15, 2025 (GLOBE NEWSWIRE) -- As rising tariffs and supply chain disruptions continue to squeeze cannabis businesses across the country, one independently owned brand based in Harlem, New York is making moves that could reshape how the industry approaches production and packaging. , a Black and Veteran-Owned company, has partnered with —a Colorado-based leader in sustainable, circular packaging—to protect profits and the planet.
With tariff hikes on imported packaging components making headlines and inflating operational costs, many cannabis brands are finding themselves stuck between shrinking margins and unreliable foreign suppliers. For Silly Nice, the answer wasn't overseas. It was finding a like-minded domestic partner focused on sustainability, efficiency, and transparency.
Founded in March 2024, Silly Nice set out to provide New Yorkers with high-quality weed while staying true to core values: environmental responsibility, transparency, and community-driven growth. Within its first year in New York's adult-use market, the brand sold over 40,000 units—and now, it's using that momentum to push for change in how cannabis brands package their products.
Partnering with Sana Packaging, Silly Nice shifted away from international suppliers toward reclaimed ocean plastic lids, 100% recycled glass jars, and renewable hemp-based boxes. The impact is real: over 694 pounds of ocean-bound plastic have already been recovered and repurposed into Silly Nice packaging.
'Sustainability isn't just a buzzword—it's a responsibility,' says LeVar Thomas, Co-Founder of Silly Nice. 'We knew we had to find a solution that didn't just respond to the tariffs—but moved us forward in a better direction. Ron and the Sana team have been instrumental in making that possible.'
Ron Basak-Smith, founder of Sana Packaging, built his company around the idea that regenerative design and closed-loop systems can—and should—define the cannabis industry's future. By offering American-made, waste-reducing materials, Sana Packaging helps brands like Silly Nice sidestep international shipping delays and volatile import fees.
The shift has proven not just sustainable, but strategic. With shorter lead times, predictable costs, and no freight containers stuck in customs, Silly Nice has improved fulfillment, reduced inventory stress, and reclaimed pricing power. That means customers get better value without sacrificing the premium, small-batch quality the brand is known for.
This collaboration comes at a time when most of the cannabis industry is facing difficult choices. Between oversaturation, price compression, and increasingly burdensome costs, few brands have managed to maintain both quality and profitability. Silly Nice's strategy offers a blueprint for how independent operators can compete—and even thrive—by investing in domestic infrastructure and environmentally conscious design.
Beyond economics, the partnership sends a message to consumers. Every Silly Nice product tells a story: one of thoughtful sourcing, environmental care, and resilience in a crowded market. Whether it's the Diamond Powder, Diamond-Frosted & Live Resin Infused Flower, Frosted Hash Ball, Bubble Hash, 510 Vape Cartridges, or 2G All-In-One Vapes, every item is sealed in packaging that mirrors the brand's dedication to quality without compromise.
And in an industry where corner-cutting often becomes the default, that commitment matters.
'Silly Nice didn't just pivot to survive—they leveled up,' says Basak-Smith. 'They saw tariffs as a trigger to do something smarter. What we've built together is a model that proves sustainability and profitability can go hand-in-hand.'
As more companies in cannabis consider reevaluating their supply chains, Silly Nice is already proving that buying American can offer long-term value. It's not just good optics—it's smart business. And for consumers who care how their weed is packaged, it's another reason to support brands that walk the talk.
About Silly NiceSilly Nice is a Harlem-based, Black and Veteran-Owned cannabis brand focused on premium concentrates and flower. Known for its eco-conscious packaging and transparent values, Silly Nice offers high-potency products across New York State including Diamond Powder, Diamond-Frosted & Live Resin Infused Flower, Bubble Hash, and more. Learn more at sillynice.com.
About Sana PackagingSana Packaging is a sustainable cannabis packaging company based in Colorado. Specializing in reclaimed ocean plastic, hemp-based boxes, and recycled glass, Sana is reimagining cannabis packaging through innovation, regeneration, and domestic supply chains. Learn more at sanapackaging.com.
Attachments
Title: The Full Silly Nice Lineup – Premium Weed with Eco-Friendly Packaging
Sustainably Sealed – Recycled Glass Jars with Ocean-Bound Plastic Lids
CONTACT: Shane Breen Silly Nice 929-375-6940 info@sillynice.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy
PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy PolTREG established Immuthera ( in Delaware to expand its presence in the U.S. market. A Pre-IND application was submitted to the FDA. The Paediatric Committee (PDCO) of the European Medicines Agency issued a positive opinion on PolTREG's Pediatric Investigation Plan (PIP) for PTG-007 in pre-symptomatic type 1 diabetes (Stage 1). Gdańsk, Poland – 13 JUNE 2025 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, announces that it has established a wholly owned subsidiary, Immuthera, a United States C Corporation, in the state of Delaware. This is a further step by PolTREG to deepen its entry into the U.S. market. 'Over recent years, PolTREG has created a platform for the development of multiple cellular therapies: polyclonal Tregs, CAR-TREGs, mulit-eidited/allogeneic CAR-Tregs, antigen-specific Tregs, and mRNA immunotherapies, all informed by our clinical experience. To fully leverage our potential, we are focusing on the execution our growth strategy in the American market by systematically bringing existing therapies, and exploring new assets into the US. We have established partnerships with several renowned entities such as Noble Capital Markets, Inc., for strategic and financial advisory services. We have also formed a strategic cooperation with the Swiss company Antion Biosciences to develop the next generation of allogeneic TREG therapies' said Prof. Piotr Trzonkowski, CEO of PolTREG. 'This expands PolTREG's project pipeline and enhances the company's attractiveness to potential strategic partners. Additionally, we with the U.S. company Kinexum Services LLC for strategic advisory regarding Immuthera's interactions with the FDA and the registration of TREG therapies in the United States. We submitted our Pre-IND meeting request to the FDA in mid-May,' added Prof. Piotr Trzonkowski. PolTREG is currently in discussions with leading American academic and clinical centers to establish collaborations and evaluate new technologies Immuthera has also begun the process of building a world-class Scientific Advisory Board comprised of globally recognized leaders in the Autoimmune and Neuroinflammatory disease. In support of PolTREG and the launch of Immuthera, Dr. Dan Shelly, Chief Business Development Officer, and Dr. Mariusz Jablonski, Chief Business Officer, will participate in the upcoming BIO International Convention 2025, taking place from June 16–19 in Boston. At BIO Drs. Shelly and Jablonski will be promoting PolTREG's current clinical and developmental pipeline while also speaking to potential partners, collaborators, and investors for Immuthera. In May, the Paediatric Committee (PDCO) of the European Medicines Agency issued a positive opinion on the Pediatric Investigation Plan (PIP) for PolTREG's investigational somatic cell therapy product, polyclonal Treg lymphocytes (PTG-007), which is aimed to prevent symptomatic type 1 diabetes in children. The PDCO's positive opinion is based on PolTREG's original preTreg clinical trial protocol, initiated in October 2024, enrolling children aged 6–16 years with Stage 1 type 1 diabetes. In its assessment, the committee recommended broadening the eligible population to include patients aged 3–18 years suggesting that the agency believes this therapy is extremely safe. This positive opinion paves the way for potential marketing authorization in the EU. To read more about the clinical trials PolTREG has completed, please click on: PolTREG manufactures its Treg therapeutics at its own GMP-certified manufacturing facility. It is the first company in the world to have administered Treg therapies to patients, and, under a hospital exemption valid in Poland, the first company to start receiving revenues from a Treg therapeutic for autoimmune disease. Its GMP manufacturing facility is one of Europe's largest and most advanced, boasting over 2,100 sqm of laboratory space, including 15 production lines. PolTREG has the option to substantially expand the facility to accommodate manufacturing of next-generation engineered therapies and cell therapies. It can ship its wide range of cellular therapy products across Europe within 24 hours. About PolTREG PolTREG is a global leader in developing autoimmune therapies based on T-regulatory cells (Tregs). Its lead product, PTG-007, autologous Treg treatment for early-onset Type-1 Diabetes (T1D) is ready for Phase 2/3 clinical testing, for which the company is seeking a partnership. PolTREG has established a robust platform encompassing a wide range of cell therapy approaches, including polyclonal TREG, CAR-TREG, allogeneic TREG, antigen-specific TREG, and TCR-TREG therapies. About Immuthera Immuthera is pioneering novel cell-based therapies for clinical development in the United States and Canada. Immuthera will be clinically developing assets initially developed by PolTREG under the US FDA regulatory framework. Immuthera will have full access to PolTREG's Research and Development capabilities along with the ability to explore novel modalities developed by US Institutions. Immuthera is currently seeking investment to pursue the manufacture and clinical development of these assets in the United States. For more information please visit For further information please contact:PolTREG Piotr TrzonkowskiChief Executive Officerir@ 512 532 401 Important information The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company's actual results may differ materially from those predicted by the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Yahoo
25 minutes ago
- Yahoo
Real Matters Inc.'s (TSE:REAL) top owners are retail investors with 60% stake, while 35% is held by institutions
Significant control over Real Matters by retail investors implies that the general public has more power to influence management and governance-related decisions A total of 25 investors have a majority stake in the company with 41% ownership Institutional ownership in Real Matters is 35% Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Every investor in Real Matters Inc. (TSE:REAL) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 60% to be precise, is retail investors. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Institutions, on the other hand, account for 35% of the company's stockholders. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. In the chart below, we zoom in on the different ownership groups of Real Matters. Check out our latest analysis for Real Matters Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. Real Matters already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Real Matters' historic earnings and revenue below, but keep in mind there's always more to the story. We note that hedge funds don't have a meaningful investment in Real Matters. FMR LLC is currently the largest shareholder, with 10% of shares outstanding. With 10% and 5.0% of the shares outstanding respectively, Manitou Investment Management Ltd. and Jason Smith are the second and third largest shareholders. A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority. While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Shareholders would probably be interested to learn that insiders own shares in Real Matters Inc.. In their own names, insiders own CA$22m worth of stock in the CA$422m company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying. The general public, who are usually individual investors, hold a substantial 60% stake in Real Matters, suggesting it is a fairly popular stock. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions. It's always worth thinking about the different groups who own shares in a company. But to understand Real Matters better, we need to consider many other factors. Be aware that Real Matters is showing 1 warning sign in our investment analysis , you should know about... If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
29 minutes ago
- Yahoo
Guide to Venture Capital & Private Equity Firms 2025: Domestic Firms, Canadian Firms, International Firms, and National & State Associations
Discover the latest 29th edition of the *Guide to Venture Capital & Private Equity Firms*, featuring profiles of 3,000 leading firms worldwide. Updated data includes firm details, partner backgrounds, and current corporate activities. Highlights include a U.S. VC dip, AI investment trends, and fintech shifts. Dublin, June 13, 2025 (GLOBE NEWSWIRE) -- The "Guide to Venture Capital & Private Equity Firms 2025: Domestic Firms, Canadian Firms, International Firms, and National & State Associations" book has been added to offering. This twenty-ninth edition of the Guide to Venture Capital & Private Equity Firms, Domestic & International is a comprehensive database of 3,000 of the most active venture capital and private equity firms operating domestically and internationally today. This new edition has been extensively updated, offering valuable, current, and detailed information to individuals, entrepreneurs, and businesses worldwide. The Guide to Venture Capital & Private Equity Firms is organized into four major sections: Domestic Firms, Canadian Firms, International Firms, and National & State Associations, each of which are listed alphabetically by name. All domestic, Canadian, and international profiles include: a mission statement, industry group preferences, portfolio companies, geographic preferences, average and minimum investments, and investment criteria. Each firm's partners are listed with extensive background information, such as education (including degree and school), professional background (including previous positions and companies), and directorships held. The specificity of both the firm and its partners add to the value of each firm's profile. Information for firms headquartered overseas includes name, phone, fax, email and website. Highlights include: VC investment in the U.S. dipped in Q3 2024, although investment in artificial intelligence (AI) remained strong. Despite the overall dip, deal sizes bumped upwards. A few IPOs occurred, but M&A activity remained curtailed. Fintech investment in the Americas showed signs of weakening, despite large deal volumes. This guide also contains five valuable indexes: College/University Index: Offers an alphabetical list of more than 1,000 educational institutions worldwide - and the venture capital executives who attended them. Each listing includes the reference number of the affiliated VC firm of the executive listed. Executive Index: An alphabetical list by last name of nearly 8,000 key partners and the listing number of their affiliated firm. Geographic Index: Organizes all firms by state for domestic listings and by country for international listings. Industry Preference Index: Alphabetically lists the more than 850 industry segments and the names of the firms that invest in them. Portfolio Companies Index: Alphabetically lists the 50,000 companies that received venture capital from a listed firm, and is referenced to that listing. Key Topics Covered: Introduction User Guide & Key KPMG Private Enterprise - Venture Pulse, Q4 2024, Global Analysis of Venture Funding KPMG - Pulse of Fintech H1 2024 DESCRIPTIVE LISTINGS Domestic Firms Canadian Firms International Firms National & State Associations INDEXES College & University Index Executive Name Index Geographic Index Industry Preference Index Portfolio Companies Index For more information about this book visit Grey House Publishing Inc About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio